Effect of nebulized magnesium sulfate in management of acute asthma attack

Comparison of nebulized magnesium sulfate with placebo in the management of patients with moderate to severe acute asthma attack presented to the emergency department

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013022412588N1

Enrollment

Registered

2013-03-18

Start date

2013-03-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asthma. Acute severe asthma

Interventions

Intervention 1: In addition of standard treatment of asthma (50 mg oral prednisolone, 2.5 mg nebulized salbutamol, 0.5 mg nebulized atrovent ), case group will receive 500 mg of nebulized magnesium s

Treatment - Drugs

Placebo

In addition of standard treatment of asthma (50 mg oral prednisolone, 2.5 mg nebulized salbutamol, 0.5 mg nebulized atrovent ), case group will receive 500 mg of nebulized magnesium sulfate (1cc of s

standard treatment of asthma (50 mg oral prednisolone, 2.5 mg nebulized salbutamol, 0.5 mg nebulized atrovent ) but instead of nebulized magnesium sulfate will bli receive 1cc of nebulized normal sal

Eligibility

Sex/Gender

All

Age

16 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria : patients with moderate to sever acute asthma attack presenting to emergency department Exclusion criteria : age less than 16 and more than 75 ,liver failure, renal failure, heart failure, fever, intubation and who are dissatisfied for trial.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Predicted Peak Expiratory Flow Rate. Timepoint: Before intervention, at 20, 40, 60 minutes after intervention. Method of measurement: Peak Flowmeter.;Hospitalization. Timepoint: After 1 hour of intervention. Method of measurement: Data will be recorded by blinded emergency resident.	—

Secondary

Measure	Time frame
Severity of dyspnea. Timepoint: Before intervention, and at 20, 40, 60 minutes after intervention. Method of measurement: Subjective dyspnea scale between 0 and 10.;Complicatins. Timepoint: After 1 hour of intervention. Method of measurement: Data will be recorded by blinded emergency resident.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Hossein Shaker

Tehran University of Medical Sciences

sh-shaker@sina.tums.ac.ir+98 21 6651 5000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026